Loading...
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Cook, G Williams, C Brown, J Cairns, D Cavenagh, J Snowden, J Ashcroft, A Fletcher, M Parrish, C Yong, K
Cook, G
Williams, C
Brown, J
Cairns, D
Cavenagh, J
Snowden, J
Ashcroft, A
Fletcher, M
Parrish, C
Yong, K
Citations
Altmetric:
Abstract
Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined. We aimed to compare high-dose melphalan plus salvage ASCT with cyclophosphamide in patients with relapsed multiple myeloma who had previously undergone ASCT.
Description
Date
2014-07
Publisher
Collections
Keywords
Type
Article
Citation
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. 2014, 15 (8):874-85 Lancet Oncol